Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Lung Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor, Adult 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Melanoma 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1 Breast Cancer Metastatic 1

Interventions

Blood Specimen Collection 38 pembrolizumab 36 Bevacizumab 22 Surveys and Questionnaires 18 Standard of Care 18 Radiotherapy 18 Exercise 17 Carboplatin 16 Nivolumab 15 atezolizumab 14 Cisplatin 14 Drug Therapy 13 Paclitaxel 12 Fluorouracil 12 Cyclophosphamide 12 Cetuximab 12 Trastuzumab 10 Leucovorin 10 Docetaxel 10 Dexamethasone 10 Pemetrexed 9 Oxaliplatin 9 Biopsy 9 pertuzumab 8 olaparib 8 Temozolomide 8 Panitumumab 8 Observation 8 Irinotecan 8 abemaciclib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasms × patritumab deruxtecan × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡